nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—PTK2B—Sunitinib—kidney cancer	0.257	0.413	CbGbCtD
Leflunomide—ABCG2—Pazopanib—kidney cancer	0.0519	0.0834	CbGbCtD
Leflunomide—ABCG2—Dactinomycin—kidney cancer	0.0475	0.0763	CbGbCtD
Leflunomide—ABCG2—Erlotinib—kidney cancer	0.0371	0.0595	CbGbCtD
Leflunomide—ABCG2—Paclitaxel—kidney cancer	0.0339	0.0545	CbGbCtD
Leflunomide—ABCG2—Sorafenib—kidney cancer	0.0301	0.0484	CbGbCtD
Leflunomide—ABCG2—Vincristine—kidney cancer	0.0292	0.047	CbGbCtD
Leflunomide—ABCG2—Sunitinib—kidney cancer	0.0244	0.0392	CbGbCtD
Leflunomide—CYP1A2—Pazopanib—kidney cancer	0.0214	0.0344	CbGbCtD
Leflunomide—CYP2C9—Capecitabine—kidney cancer	0.0201	0.0323	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—kidney cancer	0.0183	0.0293	CbGbCtD
Leflunomide—CYP1A2—Erlotinib—kidney cancer	0.0153	0.0245	CbGbCtD
Leflunomide—CYP2C9—Paclitaxel—kidney cancer	0.0126	0.0202	CbGbCtD
Leflunomide—CYP1A2—Sorafenib—kidney cancer	0.0124	0.0199	CbGbCtD
Leflunomide—CYP2C9—Sorafenib—kidney cancer	0.0112	0.018	CbGbCtD
Leflunomide—DHODH—gonad—kidney cancer	0.00339	0.126	CbGeAlD
Leflunomide—DHODH—cardiac atrium—kidney cancer	0.00339	0.126	CbGeAlD
Leflunomide—CYP1A2—urine—kidney cancer	0.003	0.112	CbGeAlD
Leflunomide—CYP2C9—urine—kidney cancer	0.00285	0.106	CbGeAlD
Leflunomide—PTK2B—renal system—kidney cancer	0.00239	0.0892	CbGeAlD
Leflunomide—PTK2B—kidney—kidney cancer	0.00232	0.0862	CbGeAlD
Leflunomide—AHR—nephron tubule—kidney cancer	0.00217	0.0807	CbGeAlD
Leflunomide—PTK2B—gonad—kidney cancer	0.00215	0.08	CbGeAlD
Leflunomide—AHR—cortex of kidney—kidney cancer	0.00185	0.069	CbGeAlD
Leflunomide—AHR—cardiac atrium—kidney cancer	0.00176	0.0657	CbGeAlD
Leflunomide—Niflumic Acid—PTGS1—kidney cancer	0.00159	0.636	CrCbGaD
Leflunomide—Niflumic Acid—PTGS2—kidney cancer	0.000906	0.364	CrCbGaD
Leflunomide—ABCG2—nephron tubule—kidney cancer	0.00084	0.0313	CbGeAlD
Leflunomide—CYP1A2—renal system—kidney cancer	0.000735	0.0274	CbGeAlD
Leflunomide—Anxiety—Paclitaxel—kidney cancer	7.91e-05	0.000323	CcSEcCtD
Leflunomide—Decreased appetite—Gemcitabine—kidney cancer	7.9e-05	0.000323	CcSEcCtD
Leflunomide—Hypersensitivity—Dactinomycin—kidney cancer	7.9e-05	0.000323	CcSEcCtD
Leflunomide—Chills—Capecitabine—kidney cancer	7.89e-05	0.000322	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	7.88e-05	0.000322	CcSEcCtD
Leflunomide—Arrhythmia—Capecitabine—kidney cancer	7.85e-05	0.000321	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Gemcitabine—kidney cancer	7.85e-05	0.00032	CcSEcCtD
Leflunomide—Discomfort—Paclitaxel—kidney cancer	7.84e-05	0.00032	CcSEcCtD
Leflunomide—Fatigue—Gemcitabine—kidney cancer	7.83e-05	0.00032	CcSEcCtD
Leflunomide—Gastrointestinal pain—Vincristine—kidney cancer	7.83e-05	0.00032	CcSEcCtD
Leflunomide—Dizziness—Sorafenib—kidney cancer	7.78e-05	0.000318	CcSEcCtD
Leflunomide—Constipation—Gemcitabine—kidney cancer	7.77e-05	0.000317	CcSEcCtD
Leflunomide—Pain—Gemcitabine—kidney cancer	7.77e-05	0.000317	CcSEcCtD
Leflunomide—Nausea—Erlotinib—kidney cancer	7.77e-05	0.000317	CcSEcCtD
Leflunomide—Alopecia—Capecitabine—kidney cancer	7.77e-05	0.000317	CcSEcCtD
Leflunomide—Dry mouth—Paclitaxel—kidney cancer	7.76e-05	0.000317	CcSEcCtD
Leflunomide—Diarrhoea—Sunitinib—kidney cancer	7.75e-05	0.000316	CcSEcCtD
Leflunomide—Mental disorder—Capecitabine—kidney cancer	7.7e-05	0.000314	CcSEcCtD
Leflunomide—Asthenia—Dactinomycin—kidney cancer	7.69e-05	0.000314	CcSEcCtD
Leflunomide—Malnutrition—Capecitabine—kidney cancer	7.65e-05	0.000312	CcSEcCtD
Leflunomide—Anaphylactic shock—Paclitaxel—kidney cancer	7.61e-05	0.000311	CcSEcCtD
Leflunomide—Abdominal pain—Vincristine—kidney cancer	7.57e-05	0.000309	CcSEcCtD
Leflunomide—Body temperature increased—Vincristine—kidney cancer	7.57e-05	0.000309	CcSEcCtD
Leflunomide—Liver function test abnormal—Doxorubicin—kidney cancer	7.56e-05	0.000309	CcSEcCtD
Leflunomide—Infection—Paclitaxel—kidney cancer	7.56e-05	0.000309	CcSEcCtD
Leflunomide—Flatulence—Capecitabine—kidney cancer	7.54e-05	0.000308	CcSEcCtD
Leflunomide—Dry skin—Doxorubicin—kidney cancer	7.51e-05	0.000306	CcSEcCtD
Leflunomide—Dysgeusia—Capecitabine—kidney cancer	7.49e-05	0.000306	CcSEcCtD
Leflunomide—Dizziness—Sunitinib—kidney cancer	7.49e-05	0.000306	CcSEcCtD
Leflunomide—Feeling abnormal—Gemcitabine—kidney cancer	7.49e-05	0.000306	CcSEcCtD
Leflunomide—Vomiting—Sorafenib—kidney cancer	7.48e-05	0.000306	CcSEcCtD
Leflunomide—Nervous system disorder—Paclitaxel—kidney cancer	7.46e-05	0.000305	CcSEcCtD
Leflunomide—Hypokalaemia—Doxorubicin—kidney cancer	7.45e-05	0.000304	CcSEcCtD
Leflunomide—Thrombocytopenia—Paclitaxel—kidney cancer	7.45e-05	0.000304	CcSEcCtD
Leflunomide—Tachycardia—Paclitaxel—kidney cancer	7.43e-05	0.000303	CcSEcCtD
Leflunomide—Rash—Sorafenib—kidney cancer	7.42e-05	0.000303	CcSEcCtD
Leflunomide—Dermatitis—Sorafenib—kidney cancer	7.41e-05	0.000303	CcSEcCtD
Leflunomide—Back pain—Capecitabine—kidney cancer	7.4e-05	0.000302	CcSEcCtD
Leflunomide—Breast disorder—Doxorubicin—kidney cancer	7.4e-05	0.000302	CcSEcCtD
Leflunomide—Skin disorder—Paclitaxel—kidney cancer	7.39e-05	0.000302	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	7.37e-05	0.000301	CcSEcCtD
Leflunomide—Headache—Sorafenib—kidney cancer	7.37e-05	0.000301	CcSEcCtD
Leflunomide—Muscle spasms—Capecitabine—kidney cancer	7.35e-05	0.0003	CcSEcCtD
Leflunomide—Hyperhidrosis—Paclitaxel—kidney cancer	7.35e-05	0.0003	CcSEcCtD
Leflunomide—Diarrhoea—Dactinomycin—kidney cancer	7.34e-05	0.0003	CcSEcCtD
Leflunomide—Anorexia—Paclitaxel—kidney cancer	7.25e-05	0.000296	CcSEcCtD
Leflunomide—Gastritis—Doxorubicin—kidney cancer	7.25e-05	0.000296	CcSEcCtD
Leflunomide—Vision blurred—Capecitabine—kidney cancer	7.21e-05	0.000294	CcSEcCtD
Leflunomide—Vomiting—Sunitinib—kidney cancer	7.2e-05	0.000294	CcSEcCtD
Leflunomide—Body temperature increased—Gemcitabine—kidney cancer	7.18e-05	0.000293	CcSEcCtD
Leflunomide—Rash—Sunitinib—kidney cancer	7.14e-05	0.000292	CcSEcCtD
Leflunomide—Dermatitis—Sunitinib—kidney cancer	7.13e-05	0.000291	CcSEcCtD
Leflunomide—Hypotension—Paclitaxel—kidney cancer	7.11e-05	0.00029	CcSEcCtD
Leflunomide—Ill-defined disorder—Capecitabine—kidney cancer	7.1e-05	0.00029	CcSEcCtD
Leflunomide—Headache—Sunitinib—kidney cancer	7.09e-05	0.00029	CcSEcCtD
Leflunomide—Asthma—Doxorubicin—kidney cancer	7.08e-05	0.000289	CcSEcCtD
Leflunomide—Influenza—Doxorubicin—kidney cancer	7.08e-05	0.000289	CcSEcCtD
Leflunomide—Anaemia—Capecitabine—kidney cancer	7.07e-05	0.000289	CcSEcCtD
Leflunomide—Hypersensitivity—Vincristine—kidney cancer	7.06e-05	0.000288	CcSEcCtD
Leflunomide—Eosinophilia—Doxorubicin—kidney cancer	7.01e-05	0.000286	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CER1—kidney cancer	7e-05	0.00068	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GPC3—kidney cancer	7e-05	0.00068	CbGpPWpGaD
Leflunomide—Nausea—Sorafenib—kidney cancer	6.99e-05	0.000285	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—MAPK1—kidney cancer	6.95e-05	0.000675	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	6.94e-05	0.000674	CbGpPWpGaD
Leflunomide—Pancreatitis—Doxorubicin—kidney cancer	6.94e-05	0.000283	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	6.93e-05	0.000283	CcSEcCtD
Leflunomide—Malaise—Capecitabine—kidney cancer	6.9e-05	0.000282	CcSEcCtD
Leflunomide—Angina pectoris—Doxorubicin—kidney cancer	6.89e-05	0.000282	CcSEcCtD
Leflunomide—Insomnia—Paclitaxel—kidney cancer	6.88e-05	0.000281	CcSEcCtD
Leflunomide—Vertigo—Capecitabine—kidney cancer	6.87e-05	0.000281	CcSEcCtD
Leflunomide—Asthenia—Vincristine—kidney cancer	6.87e-05	0.000281	CcSEcCtD
Leflunomide—Leukopenia—Capecitabine—kidney cancer	6.85e-05	0.00028	CcSEcCtD
Leflunomide—Paraesthesia—Paclitaxel—kidney cancer	6.83e-05	0.000279	CcSEcCtD
Leflunomide—Vomiting—Dactinomycin—kidney cancer	6.82e-05	0.000278	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—kidney cancer	6.81e-05	0.000278	CcSEcCtD
Leflunomide—PTK2B—Immune System—CARD11—kidney cancer	6.79e-05	0.000659	CbGpPWpGaD
Leflunomide—Dyspnoea—Paclitaxel—kidney cancer	6.78e-05	0.000277	CcSEcCtD
Leflunomide—Palpitations—Capecitabine—kidney cancer	6.76e-05	0.000276	CcSEcCtD
Leflunomide—Rash—Dactinomycin—kidney cancer	6.76e-05	0.000276	CcSEcCtD
Leflunomide—Nausea—Sunitinib—kidney cancer	6.73e-05	0.000275	CcSEcCtD
Leflunomide—Pancytopenia—Doxorubicin—kidney cancer	6.72e-05	0.000274	CcSEcCtD
Leflunomide—Dyspepsia—Paclitaxel—kidney cancer	6.7e-05	0.000273	CcSEcCtD
Leflunomide—Cough—Capecitabine—kidney cancer	6.68e-05	0.000273	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—kidney cancer	6.62e-05	0.00027	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—kidney cancer	6.62e-05	0.00027	CcSEcCtD
Leflunomide—Decreased appetite—Paclitaxel—kidney cancer	6.61e-05	0.00027	CcSEcCtD
Leflunomide—Hypertension—Capecitabine—kidney cancer	6.6e-05	0.00027	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—kidney cancer	6.58e-05	0.000269	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.57e-05	0.000268	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—kidney cancer	6.56e-05	0.000637	CbGpPWpGaD
Leflunomide—Fatigue—Paclitaxel—kidney cancer	6.56e-05	0.000268	CcSEcCtD
Leflunomide—Diarrhoea—Vincristine—kidney cancer	6.55e-05	0.000268	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—RAF1—kidney cancer	6.54e-05	0.000635	CbGpPWpGaD
Leflunomide—Pollakiuria—Doxorubicin—kidney cancer	6.54e-05	0.000267	CcSEcCtD
Leflunomide—Asthenia—Gemcitabine—kidney cancer	6.52e-05	0.000266	CcSEcCtD
Leflunomide—Myalgia—Capecitabine—kidney cancer	6.51e-05	0.000266	CcSEcCtD
Leflunomide—Arthralgia—Capecitabine—kidney cancer	6.51e-05	0.000266	CcSEcCtD
Leflunomide—Chest pain—Capecitabine—kidney cancer	6.51e-05	0.000266	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—RELA—kidney cancer	6.51e-05	0.000632	CbGpPWpGaD
Leflunomide—Pain—Paclitaxel—kidney cancer	6.51e-05	0.000266	CcSEcCtD
Leflunomide—Constipation—Paclitaxel—kidney cancer	6.51e-05	0.000266	CcSEcCtD
Leflunomide—Anxiety—Capecitabine—kidney cancer	6.49e-05	0.000265	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.47e-05	0.000264	CcSEcCtD
Leflunomide—Discomfort—Capecitabine—kidney cancer	6.43e-05	0.000263	CcSEcCtD
Leflunomide—Pruritus—Gemcitabine—kidney cancer	6.43e-05	0.000263	CcSEcCtD
Leflunomide—ABCG2—Metabolism—ACY1—kidney cancer	6.42e-05	0.000624	CbGpPWpGaD
Leflunomide—Weight decreased—Doxorubicin—kidney cancer	6.4e-05	0.000261	CcSEcCtD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	6.39e-05	0.00062	CbGpPWpGaD
Leflunomide—Hyperglycaemia—Doxorubicin—kidney cancer	6.38e-05	0.000261	CcSEcCtD
Leflunomide—Dry mouth—Capecitabine—kidney cancer	6.37e-05	0.00026	CcSEcCtD
Leflunomide—Nausea—Dactinomycin—kidney cancer	6.37e-05	0.00026	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—kidney cancer	6.35e-05	0.000259	CcSEcCtD
Leflunomide—Dizziness—Vincristine—kidney cancer	6.33e-05	0.000259	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—kidney cancer	6.31e-05	0.000258	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—kidney cancer	6.31e-05	0.000258	CcSEcCtD
Leflunomide—PTK2B—Immune System—ITPR2—kidney cancer	6.31e-05	0.000613	CbGpPWpGaD
Leflunomide—Feeling abnormal—Paclitaxel—kidney cancer	6.27e-05	0.000256	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	6.26e-05	0.000255	CcSEcCtD
Leflunomide—Gastrointestinal pain—Paclitaxel—kidney cancer	6.22e-05	0.000254	CcSEcCtD
Leflunomide—Diarrhoea—Gemcitabine—kidney cancer	6.22e-05	0.000254	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—kidney cancer	6.2e-05	0.000253	CcSEcCtD
Leflunomide—Infection—Capecitabine—kidney cancer	6.2e-05	0.000253	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—kidney cancer	6.19e-05	0.000253	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	6.19e-05	0.000601	CbGpPWpGaD
Leflunomide—Jaundice—Doxorubicin—kidney cancer	6.15e-05	0.000251	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—kidney cancer	6.15e-05	0.000251	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—kidney cancer	6.13e-05	0.00025	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—kidney cancer	6.13e-05	0.00025	CcSEcCtD
Leflunomide—Nervous system disorder—Capecitabine—kidney cancer	6.12e-05	0.00025	CcSEcCtD
Leflunomide—Thrombocytopenia—Capecitabine—kidney cancer	6.11e-05	0.00025	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—GSTT1—kidney cancer	6.11e-05	0.000593	CbGpPWpGaD
Leflunomide—Tachycardia—Capecitabine—kidney cancer	6.09e-05	0.000249	CcSEcCtD
Leflunomide—Vomiting—Vincristine—kidney cancer	6.09e-05	0.000249	CcSEcCtD
Leflunomide—Skin disorder—Capecitabine—kidney cancer	6.06e-05	0.000248	CcSEcCtD
Leflunomide—Urticaria—Paclitaxel—kidney cancer	6.04e-05	0.000247	CcSEcCtD
Leflunomide—Rash—Vincristine—kidney cancer	6.04e-05	0.000247	CcSEcCtD
Leflunomide—Hyperhidrosis—Capecitabine—kidney cancer	6.04e-05	0.000246	CcSEcCtD
Leflunomide—Dermatitis—Vincristine—kidney cancer	6.03e-05	0.000246	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—kidney cancer	6.02e-05	0.000246	CcSEcCtD
Leflunomide—Body temperature increased—Paclitaxel—kidney cancer	6.01e-05	0.000246	CcSEcCtD
Leflunomide—Abdominal pain—Paclitaxel—kidney cancer	6.01e-05	0.000246	CcSEcCtD
Leflunomide—Headache—Vincristine—kidney cancer	6e-05	0.000245	CcSEcCtD
Leflunomide—Hepatobiliary disease—Doxorubicin—kidney cancer	5.97e-05	0.000244	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SFRP2—kidney cancer	5.95e-05	0.000578	CbGpPWpGaD
Leflunomide—Epistaxis—Doxorubicin—kidney cancer	5.95e-05	0.000243	CcSEcCtD
Leflunomide—Anorexia—Capecitabine—kidney cancer	5.95e-05	0.000243	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	5.93e-05	0.000576	CbGpPWpGaD
Leflunomide—Sinusitis—Doxorubicin—kidney cancer	5.92e-05	0.000242	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—kidney cancer	5.89e-05	0.000572	CbGpPWpGaD
Leflunomide—Agranulocytosis—Doxorubicin—kidney cancer	5.89e-05	0.00024	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2—kidney cancer	5.86e-05	0.00057	CbGpPWpGaD
Leflunomide—Hypotension—Capecitabine—kidney cancer	5.83e-05	0.000238	CcSEcCtD
Leflunomide—Vomiting—Gemcitabine—kidney cancer	5.78e-05	0.000236	CcSEcCtD
Leflunomide—DHODH—Metabolism—POMC—kidney cancer	5.76e-05	0.000559	CbGpPWpGaD
Leflunomide—Rash—Gemcitabine—kidney cancer	5.73e-05	0.000234	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—PTGS1—kidney cancer	5.72e-05	0.000556	CbGpPWpGaD
Leflunomide—Dermatitis—Gemcitabine—kidney cancer	5.72e-05	0.000234	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—kidney cancer	5.69e-05	0.000233	CcSEcCtD
Leflunomide—Headache—Gemcitabine—kidney cancer	5.69e-05	0.000232	CcSEcCtD
Leflunomide—Nausea—Vincristine—kidney cancer	5.69e-05	0.000232	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.69e-05	0.000232	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	5.68e-05	0.000552	CbGpPWpGaD
Leflunomide—Rhinitis—Doxorubicin—kidney cancer	5.68e-05	0.000232	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—kidney cancer	5.66e-05	0.000231	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—kidney cancer	5.66e-05	0.000231	CcSEcCtD
Leflunomide—Insomnia—Capecitabine—kidney cancer	5.65e-05	0.000231	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—kidney cancer	5.62e-05	0.00023	CcSEcCtD
Leflunomide—Paraesthesia—Capecitabine—kidney cancer	5.61e-05	0.000229	CcSEcCtD
Leflunomide—Hypersensitivity—Paclitaxel—kidney cancer	5.61e-05	0.000229	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—kidney cancer	5.59e-05	0.000228	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—kidney cancer	5.58e-05	0.000228	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—kidney cancer	5.57e-05	0.000227	CcSEcCtD
Leflunomide—Dyspnoea—Capecitabine—kidney cancer	5.57e-05	0.000227	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	5.57e-05	0.000541	CbGpPWpGaD
Leflunomide—Urethral disorder—Doxorubicin—kidney cancer	5.55e-05	0.000227	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	5.54e-05	0.000538	CbGpPWpGaD
Leflunomide—Dyspepsia—Capecitabine—kidney cancer	5.5e-05	0.000224	CcSEcCtD
Leflunomide—PTK2B—Immune System—CTSB—kidney cancer	5.47e-05	0.000532	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PDHB—kidney cancer	5.46e-05	0.000531	CbGpPWpGaD
Leflunomide—Asthenia—Paclitaxel—kidney cancer	5.46e-05	0.000223	CcSEcCtD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	5.46e-05	0.00053	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTSD—kidney cancer	5.45e-05	0.000529	CbGpPWpGaD
Leflunomide—Decreased appetite—Capecitabine—kidney cancer	5.43e-05	0.000222	CcSEcCtD
Leflunomide—Nausea—Gemcitabine—kidney cancer	5.4e-05	0.00022	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Capecitabine—kidney cancer	5.39e-05	0.00022	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	5.38e-05	0.000523	CbGpPWpGaD
Leflunomide—Fatigue—Capecitabine—kidney cancer	5.38e-05	0.00022	CcSEcCtD
Leflunomide—Pruritus—Paclitaxel—kidney cancer	5.38e-05	0.00022	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—kidney cancer	5.36e-05	0.000219	CcSEcCtD
Leflunomide—Pain—Capecitabine—kidney cancer	5.34e-05	0.000218	CcSEcCtD
Leflunomide—Constipation—Capecitabine—kidney cancer	5.34e-05	0.000218	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—kidney cancer	5.29e-05	0.000216	CcSEcCtD
Leflunomide—PTK2B—Immune System—PSMD7—kidney cancer	5.29e-05	0.000514	CbGpPWpGaD
Leflunomide—Cardiac disorder—Doxorubicin—kidney cancer	5.26e-05	0.000215	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—GSTT1—kidney cancer	5.22e-05	0.000507	CbGpPWpGaD
Leflunomide—Diarrhoea—Paclitaxel—kidney cancer	5.21e-05	0.000213	CcSEcCtD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.18e-05	0.000503	CbGpPWpGaD
Leflunomide—Feeling abnormal—Capecitabine—kidney cancer	5.14e-05	0.00021	CcSEcCtD
Leflunomide—ABCG2—Metabolism—CCBL1—kidney cancer	5.14e-05	0.000499	CbGpPWpGaD
Leflunomide—Immune system disorder—Doxorubicin—kidney cancer	5.12e-05	0.000209	CcSEcCtD
Leflunomide—Gastrointestinal pain—Capecitabine—kidney cancer	5.11e-05	0.000208	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—kidney cancer	5.11e-05	0.000208	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	5.1e-05	0.000495	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	5.1e-05	0.000495	CbGpPWpGaD
Leflunomide—Chills—Doxorubicin—kidney cancer	5.08e-05	0.000208	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—kidney cancer	5.06e-05	0.000207	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	5.05e-05	0.000491	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	5.04e-05	0.000489	CbGpPWpGaD
Leflunomide—Dizziness—Paclitaxel—kidney cancer	5.03e-05	0.000205	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—kidney cancer	5.01e-05	0.000204	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	4.99e-05	0.000485	CbGpPWpGaD
Leflunomide—Mental disorder—Doxorubicin—kidney cancer	4.96e-05	0.000203	CcSEcCtD
Leflunomide—Urticaria—Capecitabine—kidney cancer	4.96e-05	0.000203	CcSEcCtD
Leflunomide—Abdominal pain—Capecitabine—kidney cancer	4.94e-05	0.000202	CcSEcCtD
Leflunomide—Body temperature increased—Capecitabine—kidney cancer	4.94e-05	0.000202	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—kidney cancer	4.93e-05	0.000201	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—PTGS1—kidney cancer	4.89e-05	0.000475	CbGpPWpGaD
Leflunomide—Flatulence—Doxorubicin—kidney cancer	4.86e-05	0.000198	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	4.85e-05	0.000472	CbGpPWpGaD
Leflunomide—Vomiting—Paclitaxel—kidney cancer	4.84e-05	0.000198	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—kidney cancer	4.83e-05	0.000197	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—AKAP13—kidney cancer	4.8e-05	0.000466	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP2—kidney cancer	4.8e-05	0.000466	CbGpPWpGaD
Leflunomide—Rash—Paclitaxel—kidney cancer	4.8e-05	0.000196	CcSEcCtD
Leflunomide—Dermatitis—Paclitaxel—kidney cancer	4.79e-05	0.000196	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—kidney cancer	4.77e-05	0.000195	CcSEcCtD
Leflunomide—Headache—Paclitaxel—kidney cancer	4.77e-05	0.000195	CcSEcCtD
Leflunomide—PTK2B—Immune System—PAK1—kidney cancer	4.75e-05	0.000461	CbGpPWpGaD
Leflunomide—Muscle spasms—Doxorubicin—kidney cancer	4.74e-05	0.000194	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—MAPK3—kidney cancer	4.71e-05	0.000458	CbGpPWpGaD
Leflunomide—Vision blurred—Doxorubicin—kidney cancer	4.65e-05	0.00019	CcSEcCtD
Leflunomide—PTK2B—Immune System—IFNA1—kidney cancer	4.63e-05	0.00045	CbGpPWpGaD
Leflunomide—Hypersensitivity—Capecitabine—kidney cancer	4.6e-05	0.000188	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTGS2—kidney cancer	4.59e-05	0.000446	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Doxorubicin—kidney cancer	4.58e-05	0.000187	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—kidney cancer	4.56e-05	0.000186	CcSEcCtD
Leflunomide—Nausea—Paclitaxel—kidney cancer	4.52e-05	0.000185	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—MAPK1—kidney cancer	4.49e-05	0.000436	CbGpPWpGaD
Leflunomide—Asthenia—Capecitabine—kidney cancer	4.48e-05	0.000183	CcSEcCtD
Leflunomide—ABCG2—Metabolism—PPAT—kidney cancer	4.45e-05	0.000433	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GLIPR1—kidney cancer	4.45e-05	0.000433	CbGpPWpGaD
Leflunomide—Malaise—Doxorubicin—kidney cancer	4.45e-05	0.000182	CcSEcCtD
Leflunomide—PTK2B—Immune System—EGR1—kidney cancer	4.44e-05	0.000431	CbGpPWpGaD
Leflunomide—Vertigo—Doxorubicin—kidney cancer	4.43e-05	0.000181	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	4.42e-05	0.00043	CbGpPWpGaD
Leflunomide—Pruritus—Capecitabine—kidney cancer	4.42e-05	0.00018	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—kidney cancer	4.41e-05	0.00018	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GRB7—kidney cancer	4.39e-05	0.000426	CbGpPWpGaD
Leflunomide—Palpitations—Doxorubicin—kidney cancer	4.36e-05	0.000178	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	4.32e-05	0.000419	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNA2—kidney cancer	4.31e-05	0.000419	CbGpPWpGaD
Leflunomide—Cough—Doxorubicin—kidney cancer	4.3e-05	0.000176	CcSEcCtD
Leflunomide—Diarrhoea—Capecitabine—kidney cancer	4.27e-05	0.000174	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—kidney cancer	4.26e-05	0.000174	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	4.24e-05	0.000412	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—kidney cancer	4.24e-05	0.000411	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTP1—kidney cancer	4.23e-05	0.000411	CbGpPWpGaD
Leflunomide—Arthralgia—Doxorubicin—kidney cancer	4.2e-05	0.000171	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—kidney cancer	4.2e-05	0.000171	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—kidney cancer	4.2e-05	0.000171	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—kidney cancer	4.18e-05	0.000171	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTP1—kidney cancer	4.18e-05	0.000406	CbGpPWpGaD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.17e-05	0.00017	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—kidney cancer	4.15e-05	0.000169	CcSEcCtD
Leflunomide—ABCG2—Metabolism—APRT—kidney cancer	4.14e-05	0.000402	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—FH—kidney cancer	4.14e-05	0.000402	CbGpPWpGaD
Leflunomide—Dizziness—Capecitabine—kidney cancer	4.13e-05	0.000169	CcSEcCtD
Leflunomide—Dry mouth—Doxorubicin—kidney cancer	4.11e-05	0.000168	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—ITPR2—kidney cancer	4.08e-05	0.000396	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Doxorubicin—kidney cancer	4.02e-05	0.000164	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTEN—kidney cancer	4e-05	0.000389	CbGpPWpGaD
Leflunomide—Infection—Doxorubicin—kidney cancer	4e-05	0.000163	CcSEcCtD
Leflunomide—Vomiting—Capecitabine—kidney cancer	3.97e-05	0.000162	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—kidney cancer	3.95e-05	0.000161	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—kidney cancer	3.94e-05	0.000161	CcSEcCtD
Leflunomide—Rash—Capecitabine—kidney cancer	3.94e-05	0.000161	CcSEcCtD
Leflunomide—Dermatitis—Capecitabine—kidney cancer	3.93e-05	0.000161	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—kidney cancer	3.93e-05	0.00016	CcSEcCtD
Leflunomide—Headache—Capecitabine—kidney cancer	3.91e-05	0.00016	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—kidney cancer	3.91e-05	0.00016	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	3.9e-05	0.000379	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—kidney cancer	3.89e-05	0.000378	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPC3—kidney cancer	3.89e-05	0.000378	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTM1—kidney cancer	3.89e-05	0.000378	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Doxorubicin—kidney cancer	3.89e-05	0.000159	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	3.84e-05	0.000373	CbGpPWpGaD
Leflunomide—Anorexia—Doxorubicin—kidney cancer	3.84e-05	0.000157	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	3.82e-05	0.000371	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	3.8e-05	0.000369	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CA2—kidney cancer	3.79e-05	0.000368	CbGpPWpGaD
Leflunomide—Hypotension—Doxorubicin—kidney cancer	3.76e-05	0.000154	CcSEcCtD
Leflunomide—Nausea—Capecitabine—kidney cancer	3.71e-05	0.000151	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CTNNA1—kidney cancer	3.7e-05	0.000359	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALAD—kidney cancer	3.69e-05	0.000358	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	3.69e-05	0.000358	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HSPB1—kidney cancer	3.68e-05	0.000357	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EIF4EBP1—kidney cancer	3.68e-05	0.000357	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	3.67e-05	0.000356	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.67e-05	0.00015	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—kidney cancer	3.64e-05	0.000149	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	3.64e-05	0.000353	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—kidney cancer	3.62e-05	0.000352	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTP1—kidney cancer	3.62e-05	0.000351	CbGpPWpGaD
Leflunomide—Paraesthesia—Doxorubicin—kidney cancer	3.61e-05	0.000148	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	3.61e-05	0.00035	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ST3GAL2—kidney cancer	3.6e-05	0.00035	CbGpPWpGaD
Leflunomide—Dyspnoea—Doxorubicin—kidney cancer	3.59e-05	0.000147	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	3.57e-05	0.000347	CbGpPWpGaD
Leflunomide—Dyspepsia—Doxorubicin—kidney cancer	3.54e-05	0.000145	CcSEcCtD
Leflunomide—ABCG2—Metabolism—ALDH1A1—kidney cancer	3.52e-05	0.000342	CbGpPWpGaD
Leflunomide—Decreased appetite—Doxorubicin—kidney cancer	3.5e-05	0.000143	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.47e-05	0.000142	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—kidney cancer	3.47e-05	0.000142	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—kidney cancer	3.44e-05	0.000141	CcSEcCtD
Leflunomide—Pain—Doxorubicin—kidney cancer	3.44e-05	0.000141	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—ANXA1—kidney cancer	3.42e-05	0.000332	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PSMD7—kidney cancer	3.42e-05	0.000332	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TSC1—kidney cancer	3.42e-05	0.000332	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC5A3—kidney cancer	3.37e-05	0.000328	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PGK1—kidney cancer	3.37e-05	0.000328	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTM1—kidney cancer	3.33e-05	0.000323	CbGpPWpGaD
Leflunomide—Feeling abnormal—Doxorubicin—kidney cancer	3.32e-05	0.000135	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—FLT1—kidney cancer	3.31e-05	0.000322	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—LDHB—kidney cancer	3.31e-05	0.000321	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Doxorubicin—kidney cancer	3.29e-05	0.000134	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	3.28e-05	0.000319	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ACY1—kidney cancer	3.24e-05	0.000315	CbGpPWpGaD
Leflunomide—Urticaria—Doxorubicin—kidney cancer	3.2e-05	0.000131	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—kidney cancer	3.18e-05	0.00013	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—kidney cancer	3.18e-05	0.00013	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	3.15e-05	0.000306	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	3.11e-05	0.000302	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TSC2—kidney cancer	3.08e-05	0.000299	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JUNB—kidney cancer	3.07e-05	0.000298	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PAK1—kidney cancer	3.07e-05	0.000298	CbGpPWpGaD
Leflunomide—Hypersensitivity—Doxorubicin—kidney cancer	2.97e-05	0.000121	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.9e-05	0.000281	CbGpPWpGaD
Leflunomide—Asthenia—Doxorubicin—kidney cancer	2.89e-05	0.000118	CcSEcCtD
Leflunomide—ABCG2—Metabolism—CA9—kidney cancer	2.87e-05	0.000279	CbGpPWpGaD
Leflunomide—Pruritus—Doxorubicin—kidney cancer	2.85e-05	0.000116	CcSEcCtD
Leflunomide—DHODH—Metabolism—PIK3CA—kidney cancer	2.82e-05	0.000274	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ACY1—kidney cancer	2.77e-05	0.000269	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.77e-05	0.000269	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PDHB—kidney cancer	2.76e-05	0.000268	CbGpPWpGaD
Leflunomide—Diarrhoea—Doxorubicin—kidney cancer	2.75e-05	0.000112	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—POMC—kidney cancer	2.75e-05	0.000267	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KIT—kidney cancer	2.72e-05	0.000264	CbGpPWpGaD
Leflunomide—Dizziness—Doxorubicin—kidney cancer	2.66e-05	0.000109	CcSEcCtD
Leflunomide—CYP2C9—Metabolism—CCBL1—kidney cancer	2.59e-05	0.000252	CbGpPWpGaD
Leflunomide—Vomiting—Doxorubicin—kidney cancer	2.56e-05	0.000104	CcSEcCtD
Leflunomide—Rash—Doxorubicin—kidney cancer	2.54e-05	0.000104	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—kidney cancer	2.54e-05	0.000104	CcSEcCtD
Leflunomide—Headache—Doxorubicin—kidney cancer	2.52e-05	0.000103	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—IGF2—kidney cancer	2.51e-05	0.000244	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—kidney cancer	2.5e-05	0.000243	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN2B—kidney cancer	2.5e-05	0.000243	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CRABP1—kidney cancer	2.44e-05	0.000237	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1R—kidney cancer	2.43e-05	0.000236	CbGpPWpGaD
Leflunomide—Nausea—Doxorubicin—kidney cancer	2.39e-05	9.76e-05	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.36e-05	0.00023	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PDHB—kidney cancer	2.36e-05	0.000229	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—POMC—kidney cancer	2.35e-05	0.000228	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.35e-05	0.000228	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ITPR2—kidney cancer	2.27e-05	0.00022	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPAT—kidney cancer	2.25e-05	0.000218	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GLIPR1—kidney cancer	2.25e-05	0.000218	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.22e-05	0.000216	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CCBL1—kidney cancer	2.22e-05	0.000215	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.2e-05	0.000214	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RAF1—kidney cancer	2.14e-05	0.000207	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RELA—kidney cancer	2.13e-05	0.000207	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—kidney cancer	2.11e-05	0.000205	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—FH—kidney cancer	2.09e-05	0.000203	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APRT—kidney cancer	2.09e-05	0.000203	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MTOR—kidney cancer	2.09e-05	0.000203	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD4—kidney cancer	2.08e-05	0.000202	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTT1—kidney cancer	2.07e-05	0.000201	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ACHE—kidney cancer	2.07e-05	0.000201	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.04e-05	0.000198	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2e-05	0.000195	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIF1A—kidney cancer	2e-05	0.000194	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TSC2—kidney cancer	1.99e-05	0.000194	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPC3—kidney cancer	1.97e-05	0.000191	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SCARB1—kidney cancer	1.96e-05	0.00019	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1B—kidney cancer	1.96e-05	0.00019	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS1—kidney cancer	1.94e-05	0.000188	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPAT—kidney cancer	1.92e-05	0.000187	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GLIPR1—kidney cancer	1.92e-05	0.000187	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—kidney cancer	1.92e-05	0.000186	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CA2—kidney cancer	1.91e-05	0.000186	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KDR—kidney cancer	1.91e-05	0.000186	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSMD7—kidney cancer	1.9e-05	0.000185	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	1.9e-05	0.000184	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	1.88e-05	0.000182	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALAD—kidney cancer	1.86e-05	0.000181	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—JUN—kidney cancer	1.86e-05	0.000181	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—kidney cancer	1.85e-05	0.00018	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ST3GAL2—kidney cancer	1.82e-05	0.000177	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—kidney cancer	1.8e-05	0.000175	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—BCHE—kidney cancer	1.8e-05	0.000175	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APRT—kidney cancer	1.79e-05	0.000174	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—FH—kidney cancer	1.79e-05	0.000174	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC5A5—kidney cancer	1.78e-05	0.000173	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.78e-05	0.000173	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APC—kidney cancer	1.76e-05	0.000171	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KIT—kidney cancer	1.76e-05	0.000171	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.75e-05	0.00017	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC2A1—kidney cancer	1.72e-05	0.000167	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PGK1—kidney cancer	1.7e-05	0.000166	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC5A3—kidney cancer	1.7e-05	0.000166	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPC3—kidney cancer	1.68e-05	0.000163	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—POMC—kidney cancer	1.67e-05	0.000163	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LDHB—kidney cancer	1.67e-05	0.000162	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BRAF—kidney cancer	1.65e-05	0.000161	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—RAF1—kidney cancer	1.64e-05	0.000159	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CA2—kidney cancer	1.63e-05	0.000159	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALAD—kidney cancer	1.59e-05	0.000155	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ST3GAL2—kidney cancer	1.55e-05	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK3—kidney cancer	1.54e-05	0.00015	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALDH1A1—kidney cancer	1.52e-05	0.000148	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK1—kidney cancer	1.46e-05	0.000142	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PGK1—kidney cancer	1.46e-05	0.000141	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC5A3—kidney cancer	1.46e-05	0.000141	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CA9—kidney cancer	1.45e-05	0.000141	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTP1—kidney cancer	1.43e-05	0.000139	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LDHB—kidney cancer	1.43e-05	0.000139	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.42e-05	0.000138	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—kidney cancer	1.38e-05	0.000134	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RAF1—kidney cancer	1.38e-05	0.000134	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RELA—kidney cancer	1.37e-05	0.000134	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—kidney cancer	1.37e-05	0.000133	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCB1—kidney cancer	1.36e-05	0.000132	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MTOR—kidney cancer	1.35e-05	0.000131	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTM1—kidney cancer	1.32e-05	0.000128	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—kidney cancer	1.27e-05	0.000123	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1B—kidney cancer	1.27e-05	0.000123	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1A1—kidney cancer	1.25e-05	0.000121	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CA9—kidney cancer	1.24e-05	0.00012	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—kidney cancer	1.24e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CRABP1—kidney cancer	1.23e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.21e-05	0.000118	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—kidney cancer	1.21e-05	0.000117	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JUN—kidney cancer	1.2e-05	0.000117	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—kidney cancer	1.2e-05	0.000116	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—kidney cancer	1.17e-05	0.000113	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ITPR2—kidney cancer	1.15e-05	0.000111	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.06e-05	0.000103	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CRABP1—kidney cancer	1.05e-05	0.000102	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—kidney cancer	1.05e-05	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ACHE—kidney cancer	1.04e-05	0.000101	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTT1—kidney cancer	1.04e-05	0.000101	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK3—kidney cancer	9.95e-06	9.67e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SCARB1—kidney cancer	9.89e-06	9.61e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ITPR2—kidney cancer	9.79e-06	9.51e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS1—kidney cancer	9.79e-06	9.51e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—kidney cancer	9.68e-06	9.4e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSMD7—kidney cancer	9.6e-06	9.32e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK1—kidney cancer	9.47e-06	9.2e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—POMC—kidney cancer	9.31e-06	9.04e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BCHE—kidney cancer	9.1e-06	8.84e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	9.02e-06	8.77e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC5A5—kidney cancer	8.99e-06	8.73e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—kidney cancer	8.95e-06	8.69e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ACHE—kidney cancer	8.93e-06	8.67e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTT1—kidney cancer	8.93e-06	8.67e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC2A1—kidney cancer	8.68e-06	8.43e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SCARB1—kidney cancer	8.45e-06	8.21e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.42e-06	8.18e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS1—kidney cancer	8.37e-06	8.13e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—kidney cancer	8.22e-06	7.98e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSMD7—kidney cancer	8.2e-06	7.97e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—kidney cancer	7.95e-06	7.72e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BCHE—kidney cancer	7.78e-06	7.55e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC5A5—kidney cancer	7.68e-06	7.46e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—kidney cancer	7.43e-06	7.21e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC2A1—kidney cancer	7.42e-06	7.21e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.35e-06	7.14e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTP1—kidney cancer	7.24e-06	7.03e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	7.2e-06	6.99e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCB1—kidney cancer	6.85e-06	6.66e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM1—kidney cancer	6.65e-06	6.46e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—kidney cancer	6.48e-06	6.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1A1—kidney cancer	6.31e-06	6.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.28e-06	6.1e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTP1—kidney cancer	6.19e-06	6.01e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCB1—kidney cancer	5.86e-06	5.69e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM1—kidney cancer	5.69e-06	5.52e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP1A1—kidney cancer	5.39e-06	5.24e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.18e-06	5.03e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—POMC—kidney cancer	4.7e-06	4.57e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—kidney cancer	4.57e-06	4.44e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.43e-06	4.3e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—POMC—kidney cancer	4.02e-06	3.9e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—kidney cancer	3.75e-06	3.64e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—kidney cancer	3.27e-06	3.18e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—kidney cancer	3.21e-06	3.11e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—kidney cancer	2.8e-06	2.72e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—kidney cancer	2.31e-06	2.24e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.97e-06	1.92e-05	CbGpPWpGaD
